You're right looking at Healius figures.
Reason why it would be interesting to know if AFR is talking about EBITDA or EBIT.
Just talking about Healius, interesting to see its valuation : EV/EBITDA of 30 x FY 20 (and 24 x FY 19). Perhaps due to a low basis of earnings (strong rebound during Q1 21).
However, most of Healius results come from the diagnostics business, while QScan is more radiology related, if I understood correctly. So I am interested if someone has a better (listed) comparison for Q Scan.
You're right looking at Healius figures.Reason why it would be...
Add IFT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$10.30 |
Change
0.160(1.58%) |
Mkt cap ! $9.820B | |||
| Open | High | Low | Value | Volume |
| $10.17 | $10.31 | $10.12 | $1.772M | 174.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 517 | $10.30 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $10.32 | 2282 | 8 |
View Market Depth
| Last trade - 12.59pm 02/09/2024 (20 minute delay) ? |
| IFT (ASX) Chart |